[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602586":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":25,"responsibleParty":39,"collaborators":25,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":25,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":25,"enrollmentInfo":50,"targetDuration":25,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":64,"whyStopped":25,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":25},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No Intervention Retrospective \"Before\" Group","ACTIVE_COMPARATOR","Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.",[13],"Other: No Intervention Retrospective \"Before\" Group",{"label":15,"type":16,"description":17,"interventionNames":18},"Prospective iNO Administration (\"After\" Group)","EXPERIMENTAL","Adult patients undergoing liver transplantation with prospective intervention involving intraoperative administration of inhaled nitric oxide (iNO) and prospective data collection.",[19],"Drug: Prospective iNO Administration (\"After\" Group)",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.",[15],null,{"type":6,"name":9,"description":11,"armGroupLabels":27,"otherNames":25},[9],[29],{"name":30,"affiliation":31,"role":32},"Raffael Zamper","London Health Sciences Centre","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","5196858500","13984","Raffael.PereiraCezarZamper@lhsc.on.ca",{"type":32,"investigatorFullName":30,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Anesthesiologist, Assistant Professor","100602586","effect-inhaled-nitric-oxide-in-adult-liver-transplant-100602586",false,"NCT07125443","Effect Inhaled Nitric Oxide in Adult Liver Transplant","Effect of Intraoperative Inhaled Nitric Oxide on Reperfusion Syndrome and Vasoplegia in Adult Liver Transplant Recipients: A Prospective Before-After Study","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Undergoing or underwent (for the retrospective \"before\" group) primary orthotopic liver transplantation. Retrospective data collection for retrospective group will take place between January 1, 2020 - May 31, 2025.\n* Written informed consent obtained for patients in the prospective (\"after\") group\n\nExclusion Criteria:\n\n* History of pulmonary arterial hypertension (mean pulmonary artery pressure ≥ 25 mmHg)\n* Re-transplantation\n* Acute fulminant hepatitis\n* Combined organ transplantation (e.g., liver-kidney)\n* Lack of complete data for propensity matching - Inability to communicate in the English language","ALL","18 Years",{"count":51,"type":52},260,"ESTIMATED","INTERVENTIONAL",[55],"NA","Liver transplantation remains the only cure for patients with end-stage liver disease. Despite continuous advances in medical care, ischemia-reperfusion injury (IRI) (tissue damage that occurs when blood supply is restored to an area that has been deprived of oxygen) remains a major contributor to complications with the newly transplanted liver. IRI can lead to a condition known as post-reperfusion syndrome that involves profound narrowing of blood vessels, significantly low blood pressure, and an increased requirement of medication to control blood pressure. In some cases, post-reperfusion syndrome can progress to a condition known as post-reperfusion vasoplegia which is a condition where severely low blood pressure persists even after blood flow is restored to the liver. This is often accompanied by complications such as improperly functioning kidneys, blood clotting disorders, and complications with the transplanted liver that can significantly affect patient outcomes. Recent studies have shown than inhaled nitric oxide (a gas that can relax blood vessels) can reduce the severity of IRI in the liver. This study is being conducted to determine whether the administration of inhaled nitric oxide during surgery reduces the severity of post-reperfusion syndrome and the incidence of post-reperfusion vasoplegia in adult patients undergoing liver transplantation. This is a before-and-after study design that will involve both the retrospective collection of data between the time period of January 1, 2020 - May 31, 2025 and prospective interventions involving adult liver transplant recipients.",[58,59,60],"Liver Diseases","Reperfusion Injury","Vasoplegia",[62,63],"Inhaled Nitric Oxide","Anesthesia","NOT_YET_RECRUITING","2025-08-14",{"date":67,"type":68},"2025-08-15","ACTUAL",{"date":70,"type":52},"2025-09-01",{"date":72,"type":52},"2027-01-01",{"name":5,"class":6}]